For instance, loss of EZH2 was shown to promote genomic instability, to act as a barrier to KRAS-driven inflammation and EMT or to promote therapy resistance in BC, colorectal cancer, lung cancer, acute myeloid and T-cell acute lymphoblastic leukemia, respectively [62, 64–70]. Here, KRAS is linked to lung carcinoma.